share_log

SVB Securities Upgrades Elevation Oncology to Outperform, Raises Price Target to $8

SVB Securities Upgrades Elevation Oncology to Outperform, Raises Price Target to $8

SVB Securities将Elevation Oncology上调至跑赢大盘,将目标
Benzinga ·  2023/05/30 06:59

SVB Securities analyst Andrew Berens upgrades Elevation Oncology (NASDAQ:ELEV) from Market Perform to Outperform and raises the price target from $5 to $8.

SVB Securities分析师安德鲁·贝伦斯将Elevation Oncology(纳斯达克股票代码:ELEV)从市场表现上调至跑赢大盘,并将目标股价从5美元上调至8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发